Online Only Articles

Transplantation of Macaca cynomolgus iPS-derived hematopoietic cells in NSG immunodeficient mice

CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Inserm, Paris, France;Université Paris 7, France
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Inserm, Paris, France;Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Department of Biochemistry, Faculty of Medicine Siriraj Hospital and Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Inserm, Paris, France;Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Department of Biochemistry, Faculty of Medicine Siriraj Hospital and Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand
Division of Pediatric Hematology/Oncology, Children’s Hospital Boston, and Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Inserm U967 - CEA / DSV / IRCM, Fontenay Aux Roses Cedex, France
Hôpital Antoine Béclère, Service d’Histologie Embryologie Cytogénétique, “Assistance Publique - Hôpitaux de Paris”, Clamart, France
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Inserm, Paris, France;Université Paris 7, France
Bluebirdbio, Cambridge, MA, USA
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France
Hôpital Antoine Béclère, Service d’Histologie Embryologie Cytogénétique, “Assistance Publique - Hôpitaux de Paris”, Clamart, France
Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Department of Biochemistry, Faculty of Medicine Siriraj Hospital and Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand
Division of Pediatric Hematology/Oncology, Children’s Hospital Boston, and Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Inserm, Paris, France
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Inserm, Paris, France
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Genetics Division, Department of Medicine, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, USA
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Université Paris Sud 11, France;Inserm, Paris, France
Vol. 100 No. 10 (2015): October, 2015 https://doi.org/10.3324/haematol.2015.127373